CD34 and graft versus host disease: There were no significant differences between the patients who received ATG-F and the patients who received ATG-G with respect to patient sex, age, disease stage, donor-recipient sex, conditioning regimen, HLA match, infused mononuclear cell number, infused CD34 + cell number or GVHD prophylaxis (Table 1).